middle.news
Orthocell Accelerates US Nerve Repair Sales with 45% Revenue Surge to A$13.2M
12:56pm on Monday 31st of August, 2026 AEST
•
Healthcare
Read Story
Orthocell Accelerates US Nerve Repair Sales with 45% Revenue Surge to A$13.2M
12:56pm on Monday 31st of August, 2026 AEST
Key Points
45% revenue growth to A$13.2 million
First full year of US Remplir sales with growing hospital and surgeon adoption
Manufacturing expansion approved with A$5–5.5 million investment
A$44 million cash reserves post A$30 million capital raise
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Orthocell (ASX:OCC)
OPEN ARTICLE